Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 17/20 | 0.44 |
| ▸ | SLC6A4 known ✓ | P31645 | 11/20 | 0.44 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5184692 | 0.83 | ADRA2C (0.46) | SLC6A2SLC6A4SLC6A3HRH1HTR1A | |
| Hydrochloric Acid SCHEMBL3330812 | 0.83 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HRH1HTR1A | |
| Hydrochloric Acid SCHEMBL3329665 | 0.83 | ADRA2C (0.45) | SLC6A2SLC6A4SLC6A3HRH1HTR1A | |
| Fumaric Acid SCHEMBL3325519 | 0.80 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HRH1CYP2D6 | |
| Fumaric Acid SCHEMBL3334061 | 0.80 | HRH1 (0.42) | SLC6A2SLC6A4SLC6A3HRH1HTR1A | |
| Fumaric Acid SCHEMBL3329522 | 0.80 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HRH1HTR1A | |
| Fumaric Acid SCHEMBL3329051 | 0.78 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HRH1KAT6A | |
| Fumaric Acid SCHEMBL3329876 | 0.78 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HRH1HTR1A | |
| Fumaric Acid SCHEMBL3329871 | 0.78 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HRH1HTR1A | |
| Hydrochloric Acid SCHEMBL3328273 | 0.77 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3HRH1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250775-A1 | Novel compounds | FISH PAUL V | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250775-A1 | Novel compounds | OPRL1, UGT1A1, NPSR1 | SLC6A2 133/4885SLC6A4 114/4885HRH1 929/4885 |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | SLC6A2 201/4885SLC6A4 350/4885HRH1 754/4885 |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | SLC6A2 109/4885SLC6A4 113/4885HRH1 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.